List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Researchers found that the SARS-CoV-2 infection activates the NF-κB pathway, driving unchecked inflammation that contributes to total organ failure in COVID-19 patients.
![Glioblastoma Multiforme (GBM) cells in culture [Credit: Dr Jin-Min Nam].](https://www.drugtargetreview.com/wp-content/uploads/glioblastoma-cells-750x500.jpg)
![Glioblastoma Multiforme (GBM) cells in culture [Credit: Dr Jin-Min Nam].](https://www.drugtargetreview.com/wp-content/uploads/glioblastoma-cells-e1601552379990.jpg)
According to researchers, Rab27b and epiregulin contribute to the development of radioresistance and could be targeted to improve glioblastoma patient survival.
The C5 compound targets the frameshifting element that allows SARS-CoV-2 to effectively replicate and marks the genome for destruction to stop the infection spreading.
A new study has shown that the mutated FBXO31 and RHOB genes can each alone cause cerebral palsy, offering potential drug targets.
An analysis of SARS-CoV-2 has allowed researchers to identify epitopes recognised by a large fraction of COVID-19 patients, with 10 that could be targeted by antibodies.
According to a study, the lipid sphingosine can inhibit SARS-CoV-2 infection and could potentially be delivered in a nasal spray to prevent COVID-19 infections.
New research has shown that MAIT cells are strongly activated in people with moderate to severe COVID-19 disease.
Pre-clinical studies in cells and hamsters have shown that potent antibodies from COVID-19 patients can prevent infection from SARS-CoV-2.
After finding that the circular RNA called CDR1as plays a role in driving metastasis, researchers have identified it as a potential target for lung squamous cancer.
Researchers have discovered that disrupting the Gdpd3 gene significantly reduced chronic myelogenous leukaemia relapse in mice.
Researchers have identified two molecules that explain why children experience COVID-19 differently to adults.
Scientists have found a hormone peptide called YY that presents a promising drug target for malabsorption in babies.
Scientists have demonstrated that AR-12 can inhibit SARS-CoV-2 replication and are working to initiate clinical trials evaluating the antiviral drug.
Richard Sachse discusses how immunotherapies targeting interleukin 15 (IL-15) signalling can be optimised to enhance their efficacy and limit off-target effects.
Scientists have developed a new assay that uses nanoparticles to mimic how SARS-CoV-2 infects a cell, which could be used to screen for drugs that treat COVID-19.
